US Patent 10278923 Oral dosing of GLP-1 compounds
Patent 10278923 was granted and assigned to Novo Nordisk on May, 2019 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10278923 Oral dosing of GLP-1 compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
